"10.1371_journal.pone.0116851","plos one","2015-01-23T00:00:00Z","Yoshinori Watanabe; Keiko Nakayama; Nobuhiko Taniuchi; Yasushi Horai; Chiaki Kuriyama; Kiichiro Ueta; Kenji Arakawa; Takaaki Senbonmatsu; Masaharu Shiotani","Pharmacology Research Laboratories II, Research Division, Mitsubishi Tanabe Pharma Corporation, Saitama, Japan; Safety Research Laboratory, Research Division, Mitsubishi Tanabe Pharma Corporation, Saitama, Japan; Department of Pharmacology, Saitama Medical University, Saitama, Japan","Conceived and designed the experiments: YW KN NT CK KU MS. Performed the experiments: YW KN NT YH KU. Analyzed the data: YW KN NT YH. Contributed reagents/materials/analysis tools: YW KN NT YH. Wrote the paper: YW KA TS.","Yoshinori Watanabe, Keiko Nakayama, Nobuhiko Taniuchi, Yasushi Horai, Chiaki Kuriyama, Kiichiro Ueta, Kenji Arakawa, and Masaharu Shiotani are employees of Mitsubishi Tanabe Pharma Corporation. Yoshinori Watanabe and Takaaki Senbonmatsu belong to Saitama Medical University Graduate School of Medicine. Takaaki Senbonmatsu has not received any payments for this study from Mitsubishi Tanabe Pharma Corporation. Canagliflozin was developed by Mitsubishi Tanabe Pharma Corporation in collaboration with Janssen Research & Development, LLC. The authors have declared that no competing interests exist. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","01","Yoshinori Watanabe","YW",9,FALSE,6,5,4,3,TRUE,TRUE,FALSE,0,NA,FALSE
